CoChat
Sign Up
Cited by 95

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation

Silva, Ana Luísa, Peres, Carina, Conniot, João, Matos, Ana I., Moura, Liane, Carreira, Bárbara, Sainz, Vanessa, Scomparin, Anna, Satchi-Fainaro, Ronit, Préat, Véronique, Florindo, Helena F.·2017·Seminars in Immunology
DOI 10.1016/j.smim.2017.09.003
Open this paper in CoChat — free account

Abstract

Nanotechnology-based strategies can dramatically impact the treatment, prevention and diagnosis of a wide range of diseases. Despite the unprecedented success achieved with the use of nanomaterials to address unmet biomedical needs and their particular suitability for the effective application of a personalized medicine, the clinical translation of those nanoparticulate systems has still been impaired by the limited understanding on their interaction with complex biological systems. As a result, unexpected effects due to unpredicted interactions at biomaterial and biological interfaces have been underlying the biosafety concerns raised by the use of nanomaterials. This review explores the current knowledge on how nanoparticle (NP) physicochemical and surface properties determine their interactions with innate immune cells, with particular attention on the activation of pattern-recognition receptors and inflammasome. A critical perspective will additionally address the impact of biological systems on the effect of NP on immune cell activity at the molecular level. We will discuss how the understanding of the NP-innate immune cell interactions can significantly add into the clinical translation by guiding the design of nanomedicines with particular effect on targeted cells, thus improving their clinical efficacy while minimizing undesired but predictable toxicological effects.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.smim.2017.09.003

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 270

  1. Fang, 2016, Nanoparticle-Based modulation of the immune system, Ann. Rev. Chem. Biomol. Eng., 7, 305, 10.1146/annurev-chembioeng-080615-034446 · DOI
  2. Pantic, 2011, Nanoparticles and modulation of immune responses, Sci. Prog., 94, 97, 10.3184/003685011X12979697342151 · DOI
  3. Yan, 2014, Micro- and nanotechnologies for intracellular delivery, Small, 10, 4487, 10.1002/smll.201401532 · DOI
  4. Gustafson, 2015, Nanoparticle uptake the phagocyte problem, Nano Today, 10, 487, 10.1016/j.nantod.2015.06.006 · DOI
  5. Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387
  6. Silva, 2013, Immune system targeting by biodegradable nanoparticles for cancer vaccines, J. Controlled Release, 168, 179, 10.1016/j.jconrel.2013.03.010 · DOI
  7. Silva, 2016, PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity, Hum. Vaccines Immunother., 12, 1056, 10.1080/21645515.2015.1117714 · DOI
  8. Zolnik, 2010, Nanoparticles and the immune system, Endocrinology, 151, 458, 10.1210/en.2009-1082 · DOI · Paper page
  9. Shang, 2014, Engineered nanoparticles interacting with cells: size matters, J. Nanobiotechnology, 12, 5, 10.1186/1477-3155-12-5 · DOI
  10. Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283, 10.1016/S0031-6997(24)01494-7 · DOI
  11. Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010 · DOI · Paper page
  12. Dwivedi, 2011, Impact of nanoparticles on the immune system, J. Biomed. Nanotechnol., 7, 193, 10.1166/jbn.2011.1264 · DOI
  13. Liu, 2011, Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice, Biomaterials, 32, 1657, 10.1016/j.biomaterials.2010.10.035 · DOI
  14. Byrne, 2008, The significance of nanoparticles in particle-induced pulmonary fibrosis, McGill J. Med.: MJM, 11, 43
  15. Elamanchili, 2007, Pathogen-mimicking nanoparticles for vaccine delivery to dendritic cells, J. Immunother., 30, 378, 10.1097/CJI.0b013e31802cf3e3 · DOI
  16. Demento, 2011, Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines, Trends Biotechnol., 29, 294, 10.1016/j.tibtech.2011.02.004 · DOI
  17. Dobrovolskaia, 2007, Immunological properties of engineered nanomaterials, Nat. Nanotechnol., 2, 469, 10.1038/nnano.2007.223 · DOI · Paper page
  18. Matzinger, 2002, The danger model: a renewed sense of self, Science, 296, 301, 10.1126/science.1071059 · DOI · Paper page
  19. Zhu, 2011, Cell surface signaling molecules in the control of immune responses: a tide model, Immunity, 34, 466, 10.1016/j.immuni.2011.04.008 · DOI
  20. Fearon, 1996, The instructive role of innate immunity in the acquired immune response, Science, 272, 50, 10.1126/science.272.5258.50 · DOI
  21. Mortier, 2012, Overview of the mechanisms regulating chemokine activity and availability, Immunol. Lett., 145, 2, 10.1016/j.imlet.2012.04.015 · DOI
  22. Nibbs, 2013, Immune regulation by atypical chemokine receptors, nature reviews, Immunology, 13, 815
  23. Leleux, 2013, Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective, Adv. Healthcare Mater., 2, 72, 10.1002/adhm.201200268 · DOI
  24. Janeway, 1989, Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harb. Symp. Quant. Biol., 54, 1, 10.1101/SQB.1989.054.01.003 · DOI
  25. Schenten, 2011, The control of adaptive immune responses by the innate immune system, Adv. Immunol., 109, 87, 10.1016/B978-0-12-387664-5.00003-0 · DOI
  26. Akira, 2006, Pathogen recognition and innate immunity, Cell, 124, 783, 10.1016/j.cell.2006.02.015 · DOI
  27. Kumar, 2009, Pathogen recognition in the innate immune response, Biochem. J., 420, 1, 10.1042/BJ20090272 · DOI
  28. Medzhitov, 1997, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, 388, 394, 10.1038/41131 · DOI
  29. Wesch, 2011, Modulation of γδ T cell responses by TLR ligands, Cell. Mol. Life Sci., 68, 2357, 10.1007/s00018-011-0699-1 · DOI
  30. Takeuchi, 2009, Innate immunity to virus infection, Immunol. Rev., 227, 75, 10.1111/j.1600-065X.2008.00737.x · DOI
  31. Loo, 2011, Immune signaling by RIG-I-like receptors, Immunity, 34, 680, 10.1016/j.immuni.2011.05.003 · DOI · Paper page
  32. Kanneganti, 2007, Intracellular NOD-like receptors in host defense and disease, Immunity, 27, 549, 10.1016/j.immuni.2007.10.002 · DOI
  33. Oviedo-Boyso, 2014, Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria, Mediators Inflamm., 2014, 10.1155/2014/432785 · DOI
  34. Mason, 2012, Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases, J. Innate Immun., 4, 16, 10.1159/000334247 · DOI
  35. Martinon, 2002, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β, Mol. Cell, 10, 417, 10.1016/S1097-2765(02)00599-3 · DOI · Paper page
  36. Kawai, 2009, The roles of TLRs, RLRs and NLRs in pathogen recognition, Int. Immunol., 21, 317, 10.1093/intimm/dxp017 · DOI
  37. Kamphorst, 2010, Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes, J. Immunol., 185, 3426, 10.4049/jimmunol.1001205 · DOI
  38. Satpathy, 2012, Re(de)fining the dendritic cell lineage, Nat. Immunol., 13, 1145, 10.1038/ni.2467 · DOI
  39. Roy, 2014, Interactive threats of nanoparticles to the biological system, Immunol. Lett., 158, 79, 10.1016/j.imlet.2013.11.019 · DOI
  40. Jeon, 2002, Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device, Nat. Biotechnol., 20, 826, 10.1038/nbt712 · DOI
  41. Cooper, 2009, Hidden talents of natural killers: NK cells in innate and adaptive immunity, EMBO Rep., 10, 1103, 10.1038/embor.2009.203 · DOI
  42. Jang, 2012, The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles, Biomaterials, 33, 5584, 10.1016/j.biomaterials.2012.04.041 · DOI
  43. Iwasaki, 2010, Regulation of adaptive immunity by the innate immune system, Science, 327, 291, 10.1126/science.1183021 · DOI
  44. Melief, 2008, Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines, nature reviews, Cancer, 8, 351
  45. Steinman, 1991, The dendritic cell system and its role in immunogenicity, Annu. Rev. Immunol., 9, 271, 10.1146/annurev.iy.09.040191.001415 · DOI
  46. Peres, 2016, Poly (lactic acid)-based particulate systems are promising tools for immune modulation, Actabiomaterialia, 48, 41
  47. Steinman, 1989, Immunogenicity: role of dendritic cells, Bioessays, 10, 145, 10.1002/bies.950100503 · DOI
  48. Kaiko, 2008, Immunological decision-making: how does the immune system decide to mount a helper T-cell response?, Immunology, 123, 326, 10.1111/j.1365-2567.2007.02719.x · DOI
  49. Khader, 2010, IL-17 in protective immunity to intracellular pathogens, Virulence, 1, 423, 10.4161/viru.1.5.12862 · DOI
  50. Joffre, 2012, Cross-presentation by dendritic cells, nature reviews, Immunology, 12, 557
  51. Sahay, 2010, Endocytosis of nanomedicines, J. Controlled Release, 145, 182, 10.1016/j.jconrel.2010.01.036 · DOI · Paper page
  52. Getts, 2015, Harnessing nanoparticles for immune modulation, Trends Immunol., 36, 419, 10.1016/j.it.2015.05.007 · DOI
  53. Mohammadi-Samani, 2014, PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches, Pharm. Dev. Technol., 20, 385, 10.3109/10837450.2014.882940 · DOI
  54. Link, 2012, Innate immunity mediates follicular transport of particulate but not soluble protein antigen, J. Immunol., 188, 3724, 10.4049/jimmunol.1103312 · DOI
  55. Manolova, 2008, Nanoparticles target distinct dendritic cell populations according to their size, Eur. J. Immunol., 38, 1404, 10.1002/eji.200737984 · DOI
  56. Jhaveri, 2016, Intracellular delivery of nanocarriers and targeting to subcellular organelles, Expert Opin. Drug Deliv., 13, 49, 10.1517/17425247.2015.1086745 · DOI
  57. Oyewumi, 2010, Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses, Expert Rev. Vaccines, 9, 1095, 10.1586/erv.10.89 · DOI
  58. Sharp, 2009, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome, Proc. Natl. Acad. Sci. U. S. A., 106, 870, 10.1073/pnas.0804897106 · DOI
  59. Wang, 2010, Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images, J. Nanobiotechnology, 8, 33, 10.1186/1477-3155-8-33 · DOI
  60. Arnida, 2010, Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres, J. Appl. Toxicol.: JAT, 30, 212, 10.1002/jat.1486 · DOI
  61. Huang, 2010, Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles, ACS Nano, 4, 7151, 10.1021/nn101643u · DOI
  62. Lu, 2009, Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles, Small, 5, 1408, 10.1002/smll.200900005 · DOI
  63. Oh, 2010, Cellular uptake, cytotoxicity, and innate immune response of silica-titania hollow nanoparticles based on size and surface functionality, ACS Nano, 4, 5301, 10.1021/nn100561e · DOI
  64. Varela, 2012, Quantifying size-dependent interactions between fluorescently labeled polystyrene nanoparticles and mammalian cells, J. Nanobiotechnology, 10, 39, 10.1186/1477-3155-10-39 · DOI
  65. Zauner, 2001, In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density, J. Controlled Release, 71, 39, 10.1016/S0168-3659(00)00358-8 · DOI
  66. Osaki, 2004, A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region, J. Am. Chem. Soc., 126, 6520, 10.1021/ja048792a · DOI
  67. Chono, 2007, Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification, J. Pharm. Pharmacol., 59, 75, 10.1211/jpp.59.1.0010 · DOI
  68. Cortez, 2007, Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells, ACS Nano, 1, 93, 10.1021/nn700060m · DOI
  69. Foged, 2005, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model, Int. J. Pharm., 298, 315, 10.1016/j.ijpharm.2005.03.035 · DOI
  70. Ban, 2012, Effect of submicron and nano-iron oxide particles on pulmonary immunity in mice, Toxicol. Lett., 210, 267, 10.1016/j.toxlet.2012.02.004 · DOI
  71. Kim, 2011, Cytotoxicity of, and innate immune response to, size-controlled polypyrrole nanoparticles in mammalian cells, Biomaterials, 32, 2342, 10.1016/j.biomaterials.2010.11.080 · DOI
  72. Lim, 2012, The effects of sub-lethal concentrations of silver nanoparticles on inflammatory and stress genes in human macrophages using cDNA microarray analysis, Biomaterials, 33, 4690, 10.1016/j.biomaterials.2012.03.006 · DOI
  73. Park, 2011, Size dependent macrophage responses and toxicological effects of Ag nanoparticles, Chem. Commun., 47, 4382, 10.1039/c1cc10357a · DOI
  74. Pan, 2007, Size-dependent cytotoxicity of gold nanoparticles, Small, 3, 1941, 10.1002/smll.200700378 · DOI
  75. Patravale, 2014, Potential of nanocarriers in antigen delivery: the path to successful vaccine delivery, Nanocarriers, 1, 10.2478/nanca-2014-0001 · DOI
  76. Joshi, 2013, Biodegradable particles as vaccine delivery systems: size matters, AAPS J., 15, 85, 10.1208/s12248-012-9418-6 · DOI
  77. Fifis, 2004, Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors, J. Immunol., 173, 3148, 10.4049/jimmunol.173.5.3148 · DOI
  78. Vandana, 2014, Potential of nanocarriers in antigen delivery: the path to successful vaccine delivery, Nanocarriers, 1, 10
  79. Albanese, 2012, The effect of nanoparticle size, shape, and surface chemistry on biological systems, Annu. Rev. Biomed. Eng., 14, 1, 10.1146/annurev-bioeng-071811-150124 · DOI · Paper page
  80. Fadeel, 2012, Clear and present danger? Engineered nanoparticles and the immune system, Swiss Med. Wkly., 142, w13609
  81. Silva, 2015, Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation, Vaccine, 33, 847, 10.1016/j.vaccine.2014.12.059 · DOI
  82. Verma, 2010, Effect of surface properties on nanoparticle–cell interactions, Small, 6, 12, 10.1002/smll.200901158 · DOI
  83. Seong, 2004, Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, nature reviews, Immunology, 4, 469
  84. Badiee, 2013, Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends, Vaccine, 31, 735, 10.1016/j.vaccine.2012.11.068 · DOI
  85. Xie, 2007, Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells, Adv. Mater., 19, 3163, 10.1002/adma.200701975 · DOI
  86. Üner, 2007, Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives, Int. J. Nanomed., 2, 289
  87. Sheng, 2009, In vitro macrophage uptake and in vivo biodistribution of PLA–PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content, J. Mater. Sci., 20, 1881
  88. Środa, 2005, Repeated injections of PEG-PE liposomes generate anti-PEG antibodies, Cell. Mol. Biol. Lett., 10, 37
  89. Dams, 2000, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes, J. Pharmacol. Exp. Ther., 292, 1071, 10.1016/S0022-3565(24)35391-1 · DOI
  90. Verhoef, 2014, Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics, Drug Discov. Today, 19, 1945, 10.1016/j.drudis.2014.08.015 · DOI
  91. Chambers, 2007, Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation, Exp. Biol. Med., 232, 958
  92. Rao, 2015, Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance, Small, 11, 6225, 10.1002/smll.201502388 · DOI
  93. Chellat, 2005, Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles, Biomaterials, 26, 961, 10.1016/j.biomaterials.2004.04.006 · DOI
  94. Shi, 2012, Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells, Int. J. Nanomed., 7, 5593
  95. Silva, 2014, Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach, Nanomedicine, 9, 2639, 10.2217/nnm.14.135 · DOI
  96. Carrillo-Conde, 2011, Mannose-functionalized pathogen-like polyanhydride nanoparticles target C-type lectin receptors on dendritic cells, Mol. Pharm., 8, 1877, 10.1021/mp200213r · DOI
  97. Macho-Fernandez, 2014, Targeted delivery of alpha-galactosylceramide to CD8alpha+ dendritic cells optimizes type I NKT cell-based antitumor responses, J. Immunol., 193, 961, 10.4049/jimmunol.1303029 · DOI
  98. Cruz, 2014, Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study, J. Controlled Release, 192, 209, 10.1016/j.jconrel.2014.07.040 · DOI
  99. Souris, 2010, Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles, Biomaterials, 31, 5564, 10.1016/j.biomaterials.2010.03.048 · DOI
  100. Bueter, 2011, Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis, J. Biol. Chem., 286, 35447, 10.1074/jbc.M111.274936 · DOI
  101. Lucarelli, 2004, Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles, Eur. Cytokine Netw., 15, 339
  102. Yang, 2012, Inflammasome formation and IL-1β release by human blood monocytes in response to silver nanoparticles, Biomaterials, 33, 6858, 10.1016/j.biomaterials.2012.06.016 · DOI
  103. Luna-Gomes, 2015, Silica-induced inflammasome activation in macrophages: role of ATP and P2×7 receptor, Immunobiology, 220, 1101, 10.1016/j.imbio.2015.05.004 · DOI
  104. Salvador-Morales, 2006, Complement activation and protein adsorption by carbon nanotubes, Mol. Immunol., 43, 193, 10.1016/j.molimm.2005.02.006 · DOI
  105. Lonez, 2014, Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways, Nanomedicine, 10, 775, 10.1016/j.nano.2013.12.003 · DOI
  106. Brown, 2001, Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines, Toxicol. Appl. Pharmacol., 175, 191, 10.1006/taap.2001.9240 · DOI
  107. Nygaard, 2004, The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass, Toxicol. Sci., 82, 515, 10.1093/toxsci/kfh287 · DOI
  108. Chuang, 2015, Surface area as a dose metric for carbon black nanoparticles: a study of oxidative stress, DNA single-strand breakage and inflammation in rats, Atmos. Environ., 106, 329, 10.1016/j.atmosenv.2015.02.014 · DOI
  109. Mendoza, 2014, Silica nanoparticles induce oxidative stress and inflammation of human peripheral blood mononuclear cells, Cell Stress Chaperones, 19, 777, 10.1007/s12192-014-0502-y · DOI
  110. Winter, 2011, Activation of the inflammasome by amorphous silica and TiO2 nanoparticles in murine dendritic cells, Nanotoxicology, 5, 326, 10.3109/17435390.2010.506957 · DOI
  111. Shahbazi, 2013, The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility, Biomaterials, 34, 7776, 10.1016/j.biomaterials.2013.06.052 · DOI
  112. Lee, 2011, The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis, Biomaterials, 32, 9434, 10.1016/j.biomaterials.2011.08.042 · DOI
  113. Kumar, 2011, Pathogen recognition by the innate immune system, Int. Rev. Immunol., 30, 16, 10.3109/08830185.2010.529976 · DOI
  114. Peeters, 2013, Silica induces NLRP3 inflammasome activation in human lung epithelial cells, Part. Fibre Toxicol., 10, 3, 10.1186/1743-8977-10-3 · DOI
  115. Sun, 2013, Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles, ACS Nano, 7, 10834, 10.1021/nn404211j · DOI
  116. Martinon, 2006, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, 440, 237, 10.1038/nature04516 · DOI · Paper page
  117. Gustafsson, 2011, Lung exposure of titanium dioxide nanoparticles induces innate immune activation and long-lasting lymphocyte response in the Dark Agouti rat, J. Immunotoxicol., 8, 111, 10.3109/1547691X.2010.546382 · DOI
  118. Kononenko, 2015, Nanoparticle interaction with the immune system, Arhiv za higijenu rada i toksikologiju, 66, 97, 10.1515/aiht-2015-66-2582 · DOI
  119. Pulskamp, 2007, Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants, Toxicol. Lett., 168, 58, 10.1016/j.toxlet.2006.11.001 · DOI
  120. Vallhov, 2006, The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications, Nano Lett., 6, 1682, 10.1021/nl060860z · DOI
  121. Szeto, 2016, Materials design at the interface of nanoparticles and innate immunity, J. Mater. Chem. B Mater. Biol. Med., 4, 1610, 10.1039/C5TB01825K · DOI
  122. Lieder, 2013, Endotoxins affect bioactivity of chitosan derivatives in cultures of bone marrow-derived human mesenchymal stem cells, Acta Biomater., 9, 4771, 10.1016/j.actbio.2012.08.043 · DOI
  123. Neagu, 2017, Protein bio-corona: critical issue in immune nanotoxicology, Arch. Toxicol., 91, 1031, 10.1007/s00204-016-1797-5 · DOI
  124. Darabi Sahneh, 2013, Dynamics of nanoparticle-protein corona complex formation: analytical results from population balance equations, PLoS One, 8, e64690, 10.1371/journal.pone.0064690 · DOI
  125. Li, 2013, Computational and experimental characterizations of silver nanoparticle-apolipoprotein biocorona, J. Phys. Chem. B, 117, 13451, 10.1021/jp4061158 · DOI
  126. Monopoli, 2012, Biomolecular coronas provide the biological identity of nanosized materials, Nat. Nanotechnol., 7, 779, 10.1038/nnano.2012.207 · DOI · Paper page
  127. Afratis, 2012, Glycosaminoglycans: key players in cancer cell biology and treatment, FEBS J., 279, 1177, 10.1111/j.1742-4658.2012.08529.x · DOI
  128. Bouris, 2015, Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells, Matrix Biol., 43, 42, 10.1016/j.matbio.2015.02.008 · DOI
  129. Lundqvist, 2011, The evolution of the protein Corona around nanoparticles: a test study, ACS Nano, 5, 7503, 10.1021/nn202458g · DOI · Paper page
  130. Salvati, 2013, Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nat. Nanotechnol., 8, 137, 10.1038/nnano.2012.237 · DOI · Paper page
  131. Maiorano, 2010, Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response, ACS Nano, 4, 7481, 10.1021/nn101557e · DOI · Paper page
  132. Dutta, 2007, Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials, Toxicol. Sci., 100, 303, 10.1093/toxsci/kfm217 · DOI
  133. Deng, 2009, Differential plasma protein binding to metal oxide nanoparticles, Nanotechnology, 20, 455101, 10.1088/0957-4484/20/45/455101 · DOI
  134. Lynch, 2008, Protein-nanoparticle interactions, Nano Today, 3, 40, 10.1016/S1748-0132(08)70014-8 · DOI
  135. Cox, 1999, Identification of platination sites on human serum transferrin using (13)C and (15)N NMR spectroscopy, J. Biol. Inorg. Chem.: JBIC, 4, 621, 10.1007/s007750050386 · DOI
  136. Rybak-Smith, 2011, Effect of functionalization of carbon nanotubes with psychosine on complement activation and protein adsorption, J. Biomed. Nanotechnol., 7, 830, 10.1166/jbn.2011.1347 · DOI
  137. Chithrani, 2007, Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes, Nano Lett., 7, 1542, 10.1021/nl070363y · DOI
  138. Pozzi, 2014, Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells, Nanoscale, 6, 2782, 10.1039/c3nr05559k · DOI · Paper page
  139. La-Beck, 2017, Nanoparticle interactions with the immune system: clinical implications for liposome-Based cancer chemotherapy, Front. Immunol., 8, 416, 10.3389/fimmu.2017.00416 · DOI
  140. Mahmoudi, 2011, Protein-nanoparticle interactions: opportunities and challenges, Chem. Rev., 111, 5610, 10.1021/cr100440g · DOI
  141. Mahmoudi, 2011, Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis, ACS Chem. Neurosci., 2, 118, 10.1021/cn100100e · DOI
  142. Cedervall, 2017, Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, PNAS, 104, 2050, 10.1073/pnas.0608582104 · DOI · Paper page
  143. Fadeel, 2013, Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 5, 111, 10.1002/wnan.1206 · DOI
  144. Walkey, 2012, Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment, Chem. Soc. Rev., 41, 2780, 10.1039/C1CS15233E · DOI · Paper page
  145. Nel, 2009, Understanding biophysicochemical interactions at the nano-bio interface, Nat. Mater., 8, 543, 10.1038/nmat2442 · DOI · Paper page
  146. Shang, 2014, Engineered nanoparticles interacting with cells – size matters, J. Nanobiotechnol., 12
  147. Moyano, 2012, Nanoparticle hydrophobicity dictates immune response, J. Am. Chem. Soc., 134, 3965, 10.1021/ja2108905 · DOI
  148. Fadeel, 2015, Keeping it real: the importance of material characterization in nanotoxicology, Biochem. Biophys. Res. Commun., 468, 498, 10.1016/j.bbrc.2015.06.178 · DOI
  149. Rybak-Smith, 2011, Complement activation by carbon nanotubes, Adv. Drug Deliv. Rev., 63, 1031, 10.1016/j.addr.2011.05.012 · DOI
  150. Deng, 2011, Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation, Nat. Nanotechnol., 6, 39, 10.1038/nnano.2010.250 · DOI
  151. Yu, 2014, Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry, ACS Nano, 26, 7687, 10.1021/nn504186b · DOI
  152. Hwang, 2008, Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment, Mol. Immunol., 45, 2570, 10.1016/j.molimm.2007.12.019 · DOI
  153. Salvador-Morales, 2006, Complement activation and protein adsorption by carbon nanotubes, Mol. Immunol., 43, 193, 10.1016/j.molimm.2005.02.006 · DOI
  154. Reddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol., 25, 1159, 10.1038/nbt1332 · DOI
  155. Kim, 2015, Multivalent polymer nanocomplex targeting endosomal receptor of immune cells for enhanced antitumor and systemic memory response, Angew. Chem. Int. Ed., 54, 8139, 10.1002/anie.201501380 · DOI
  156. Ruiz-de-Angulo, 2016, Microdosed lipid-coated 67Ga-magnetite enhances antigen-specific immunity by image tracked delivery of antigen and CpG to lymph nodes, ACS Nano, 10, 1602, 10.1021/acsnano.5b07253 · DOI
  157. Kim, 2012, Multifunctional hybrid nanoconjugates for efficient in vivo delivery of immunomodulating oligonucleotides and enhanced antitumor immunity, Angew. Chem. Int. Ed., 51, 9670, 10.1002/anie.201204989 · DOI
  158. Ultimo, 2016, Targeting innate immunity with dsRNA-conjugated mesoporous silica nanoparticles promotes antitumor effects on breast cancer cells, Chem.–A Eur. J., 22, 1582, 10.1002/chem.201504629 · DOI
  159. Rosalia, 2015, CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, Biomaterials, 40, 88, 10.1016/j.biomaterials.2014.10.053 · DOI
  160. Fox, 2014, A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7, J. Nanobiotechnol., 12, 17, 10.1186/1477-3155-12-17 · DOI
  161. Li, 2013, Generation of effector memory T cell–based mucosal and systemic immunity with pulmonary nanoparticle vaccination, Sci. Transl. Med., 5, 204ra130, 10.1126/scitranslmed.3006516 · DOI
  162. Tamayo, 2010, Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation, Clin. Vaccine Immunol., 17, 1356, 10.1128/CVI.00164-10 · DOI
  163. Cubillos-Ruiz, 2009, Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, J. Clin. Invest., 119, 2231
  164. Tsai, 2012, Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages, J. Immunol., 188, 68, 10.4049/jimmunol.1100344 · DOI
  165. Shaunak, 2004, Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation, Nat. Biotechnol., 22, 977, 10.1038/nbt995 · DOI
  166. Demento, 2009, Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy, Vaccine, 27, 3013, 10.1016/j.vaccine.2009.03.034 · DOI · Paper page
  167. Lonez, 2014, Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways, Nanomed. Nanotechnol. Biol. Med., 10, 775, 10.1016/j.nano.2013.12.003 · DOI
  168. Kusaka, 2014, Effect of silica particle size on macrophage inflammatory responses, PLoS One, 9, e92634, 10.1371/journal.pone.0092634 · DOI
  169. Yazdi, 2010, Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β, Proc. Natl. Acad. Sci., 107, 19449, 10.1073/pnas.1008155107 · DOI · Paper page
  170. Szeto, 2016, Materials design at the interface of nanoparticles and innate immunity, J. Mater. Chem. B, 4, 1610, 10.1039/C5TB01825K · DOI
  171. Merle, 2015, Complement system part I–molecular mechanisms of activation and regulation, Front. Immunol., 6, 10.3389/fimmu.2015.00262 · DOI · Paper page
  172. Liu, 2013, Engineering biomaterial-associated complement activation to improve vaccine efficacy, Biomacromolecules, 14, 3321, 10.1021/bm400930k · DOI
  173. Reddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol., 25, 1159, 10.1038/nbt1332 · DOI
  174. Da Costa, 1999, Humoral response to herpes simplex virus is complement-dependent, Proc. Natl. Acad. Sci., 96, 12708, 10.1073/pnas.96.22.12708 · DOI
  175. Gustavsson, 1995, Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction, J. Immunol., 154, 6524, 10.4049/jimmunol.154.12.6524 · DOI
  176. Hajishengallis, 2010, Crosstalk pathways between Toll-like receptors and the complement system, Trends Immunol., 31, 154, 10.1016/j.it.2010.01.002 · DOI
  177. Camacho, 2011, Poly (methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators, Vaccine, 29, 7130, 10.1016/j.vaccine.2011.05.072 · DOI
  178. Mueller, 2015, Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity, Mol. Pharm., 12, 1356, 10.1021/mp500589c · DOI
  179. Al-Hanbali, 2006, Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption, J. Nanosci. Nanotechnol., 6, 3126, 10.1166/jnn.2006.406 · DOI
  180. Fornaguera, 2015, Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies, Nanoscale, 7, 6045, 10.1039/C5NR00733J · DOI
  181. Szebeni, 2012, Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome, Nanomed. Nanotechnol. Biol. Med., 8, 176, 10.1016/j.nano.2011.06.003 · DOI
  182. Szebeni, 2011, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev., 63, 1020, 10.1016/j.addr.2011.06.017 · DOI
  183. Moghimi, 2010, Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: the challenges ahead, J. Controlled Release, 146, 175, 10.1016/j.jconrel.2010.04.003 · DOI
  184. Moghimi, 2012, Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward, Adv. Drug Deliv. Rev., 64, 1385, 10.1016/j.addr.2012.05.010 · DOI
  185. Nilsson, 2007, The role of complement in biomaterial-induced inflammation, Mol. Immunol., 44, 82, 10.1016/j.molimm.2006.06.020 · DOI · Paper page
  186. Seung-Yong, 2004, Opinion: hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, nature reviews, Immunology, 4, 469
  187. Thomas, 2011, Engineering complement activation on polypropylene sulfide vaccine nanoparticles, Biomaterials, 32, 2194, 10.1016/j.biomaterials.2010.11.037 · DOI
  188. Hussain, 2012, Interactions of nanomaterials with the immune system, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 4, 169, 10.1002/wnan.166 · DOI
  189. Wibroe, 2017, Complement sensing of nanoparticles and nanomedicines, Vol. 2, 365
  190. Thomas, 2014, Physicochemical signatures of nanoparticle-dependent complement activation, Comput. Sci. Discov., 7, 015003, 10.1088/1749-4699/7/1/015003 · DOI
  191. Siegler, 2016, Nanomedicine targeting the tumor microenvironment: therapeutic strategies to inhibit angiogenesis, remodel matrix, and modulate immune responses, J. Cell. Immunother., 2, 69, 10.1016/j.jocit.2016.08.002 · DOI
  192. Markiewski, 2008, Modulation of the antitumor immune response by complement, Nat. Immunol., 9, 1225, 10.1038/ni.1655 · DOI
  193. Chanan-Khan, 2003, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions, Ann. Oncol., 14, 1430, 10.1093/annonc/mdg374 · DOI · Paper page
  194. Banda, 2014, Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum, Part. Fibre Toxicol., 11, 64, 10.1186/s12989-014-0064-2 · DOI
  195. Rampton, 2014, Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management, Haematologica, 99, 1671, 10.3324/haematol.2014.111492 · DOI
  196. Silva, 2015, In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model, J. Controlled Release, 198, 91, 10.1016/j.jconrel.2014.11.033 · DOI
  197. Climent, 2014, Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses, Vaccine, 32, 6266, 10.1016/j.vaccine.2014.09.010 · DOI
  198. Warashina, 2016, A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells, J. Controlled Release, 225, 183, 10.1016/j.jconrel.2016.01.042 · DOI
  199. Hafner, 2016, Surface-assembled poly(I:C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and bystander cell stimulation, Int. J. Pharm., 514, 176, 10.1016/j.ijpharm.2016.07.042 · DOI
  200. Lin, 2013, Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy, PLoS One, 8, e63550, 10.1371/journal.pone.0063550 · DOI

200 of 270 shown

Cited by

Sorted by citations

See all 95

Metadata

Authors
Silva, A. L., Peres, C., Conniot, J., Matos, A. I., Moura, L., Carreira, B., Sainz, V., Scomparin, A., Satchi-Fainaro, R., Préat, V., & Florindo, H. F.
Venue
Seminars in Immunology
Publisher
Elsevier BV
Published
2017-12
Volume
34
Pages
3-24
ISSN
1044-5323
DOI
10.1016/j.smim.2017.09.003
Cited by
95
References
12
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • The Fundaçãopara a Ciência e a Tecnologia, Ministério da Ciência, Tecnologia e Ensino Superior (FCT-MCTES), Portugal (SFRH/BD/87591/2012, PD/BD/113959/2015, SFRH/BD/87150/2012, SFRH/BD/87869/2012, SFRH/BPD/94111/2013)
  • The Israeli Ministry of Health (3-13620)
  • The FCT-MCTES
  • The Fonds National de la Recherche Scientifique (FNRS)
  • European Research Council (ERC)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review